RSI low/high Values: [ 25 - 75 ]
* StockInvest.us uses dynamically calculated RSI max/min levels to determine when stock is oversold or overbought based on historical behavior.
AI Analysis of MGNX
Powered by GPT-4
Upgraded!
Stock Analysis
Risk Assessment
Trading Strategy

High volatility in MacroGenics stock price on Wednesday which ended trading at $15.55
(Updated on May 01, 2024)

Sell candidate since Apr 25, 2024 Gain 8.21% PDF

The MacroGenics stock price gained 5.21% on the last trading day (Wednesday, 1st May 2024), rising from $14.78 to $15.55. During the last trading day the stock fluctuated 10.36% from a day low at $14.77 to a day high of $16.30. The price has fallen in 6 of the last 10 days and is down by -3.42% for this period. Volume has increased on the last day along with the price, which is a positive technical sign, and, in total, 243 thousand more shares were traded than the day before. In total, 938 thousand shares were bought and sold for approximately $14.59 million.

The stock lies in the middle of a very wide and falling trend in the short term and further fall within the trend is signaled. Given the current short-term trend, the stock is expected to fall -10.82% during the next 3 months and, with a 90% probability hold a price between $11.13 and $17.77 at the end of this 3-month period.

Ready to grow your portfolio? Here's your beginner's guide to opening a free brokerage account.

MGNX Signals & Forecast

There are mixed signals in the stock today. The MacroGenics stock holds a buy signal from the short-term Moving Average; at the same time, however, the long-term average holds a general sell signal. Since the longterm average is above the short-term average there is a general sell signal in the stock giving a more negative forecast for the stock. On further gains, the stock will meet resistance from the long-term Moving Average at $15.83. On a fall, the stock will find some support from the short-term average at $15.14. A break-up through the long-term average will give another buy signal, while a fall below the short-term average will add another sell signal and strengthen the general signal. A sell signal was issued from a pivot top point on Thursday, April 11, 2024, and so far it has fallen -15.99%. Further fall is indicated until a new bottom pivot has been found. Furthermore, there is currently a sell signal from the 3 month Moving Average Convergence Divergence (MACD). Volume is rising along with the price. This is considered to be a good technical signal.

Support, Risk & Stop-loss for MacroGenics stock

MacroGenics finds support from accumulated volume at $15.45 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.

This stock may move much during the day (volatility) and with a large prediction interval from the Bollinger Band this stock is considered to be "high risk". During the last day, the stock moved $1.53 between high and low, or 10.36%. For the last week, the stock has had daily average volatility of 7.46%.

Our recommended stop-loss: We hold a negative evaluation for this stock. No stop-loss is set.

Trading Expectations (MGNX) For The Upcoming Trading Day Of Thursday 2nd

For the upcoming trading day on Thursday, 2nd we expect MacroGenics to open at $15.54, and during the day (based on 14 day Average True Range), to move between $14.41 and $16.69, which gives a possible trading interval of +/-$1.14 (+/-7.30%) up or down from last closing price. If MacroGenics takes out the full calculated possible swing range there will be an estimated 14.61% move between the lowest and the highest trading price during the day.

Since the stock is closer to the support from accumulated volume at $15.45 (0.68%) than the resistance at $15.93 (2.44%), our systems sees the trading risk/reward intra-day as attractive and believe profit can be made before the stock reaches first resistance..

Is MacroGenics stock A Buy?

MacroGenics holds several negative signals and we believe that it will still perform weakly in the next couple of days or weeks. We, therefore, hold a negative evaluation of this stock.

Current score: -1.368 Sell Candidate Unchanged

Predicted Opening Price for MacroGenics of Thursday, May 2, 2024

Fair opening price May 2, 2024 Current price
$15.54 ( 0.0643%) $15.55

The predicted opening price is based on yesterday's movements between high, low, and closing price.

Trading levels for MGNX

Fibonacci Support & Resistance Levels

Level Price
Resistance R3 17.07 9.77 %
R2 16.49 6.02 %
R1 16.12 3.69 %
Current price: 15.55
Support S1 14.96 -3.82 %
S2 14.59 -6.14 %
S3 14.01 -9.90 %

Accumulated Volume Support & Resistance Levels

Level Price
Resistance R3 17.78 14.34 %
R2 17.43 12.09 %
R1 15.93 2.44 %
Current price 15.55
Support S1 15.45 -0.675%
S2 15.39 -1.03%
S3 13.67 -12.09%

FAQ

What is the symbol for MacroGenics Stock and on which exchange is it traded?
The symbol for MacroGenics is MGNX and it is traded on the NASDAQ (NASDAQ Stock Exchange).

Should I buy or sell MacroGenics Stock?
MacroGenics holds several negative signals and we believe that it will still perform weakly in the next couple of days or weeks. We, therefore, hold a negative evaluation of this stock.

How to buy MacroGenics Stock?
MacroGenics Stock can be purchased through just about any brokerage firm, including online brokerage services.
Click here for our free guide on how to buy MacroGenics Stock.

What's the current price of MacroGenics Stock?
As of the end of day on the May 01, 2024, the price of an MacroGenics (MGNX) share was $15.55.

What is the 52-week high and low for MacroGenics Stock?
The 52-week high for MacroGenics Stock is $21.88 and the 52-week low is $4.29.

What is the market capitalization of MacroGenics Stock?
As of the May 01, 2024, the market capitalization of MacroGenics is 916.795M.

When is the next earnings date for MacroGenics?
The upcoming earnings date for MacroGenics is May 21, 2024.
Click to get the best stock tips daily for free!

About MacroGenics

MacroGenics MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The... MGNX Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT